Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifermin for Oral Mucositis in Head and Neck Cancer
NCT00131638Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2005
- Primary completion
- Nov 2007
- Modality
- Cytokines & Interferons
01
Overview
Phase 3, randomised, double-blind trial in oral mucositis (OM) comparing Palifermin with Placebo (2 arms). Primary endpoint: Incidence percentage of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale) up to 24 weeks. Started Jan 2005; status: completed.
02
Drugs
palifermin
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT00131638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131638.